A company dedicated to treatment products for Alzheimer's care announced yesterday a renewed consulting agreement with its founding scientitst.
Dr Peter Davies will remain at Applied NeuroSolutions for another three years thanks to the renewal agreement, which allows the doctor "to advance the development of the company's novel diagnostic and therapeutic programs."
"We have made significant progress and are focused on what I consider to be truly groundbreaking achievements to create products to effectively diagnose and treat Alzheimer's disease," said Davies.
Though he was not specific, Davies said the company was "targeting achievement of significant milestones in early 2009" in the area of Alzheimer's care.
Currently, the doctor and the company have been working on a "serum-based diagnostic test" for Alzheimer's, which if brought into the market may lead to early detection of the debilitating disease.
Though there is no cure, early detection is the best way for patients and caregivers to treat the disease, according to the Alzheimer's Association.
An estimated 5.2 million people in the U.S. are currently living with Alzheimer's disease. By 2030, it's estimated the number of individuals aged 65 and older with the disease will reach 7.7 million.